The designation will provide Lundbeck with the possibility of rolling reviews and detailed guidance to streamline the drug ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 ...

Alterity Therapeutics Limited (market cap: $40 million), a pharmaceutical company specializing in the development of therapeutic drugs, has secured A$40 million in funding to advance the development ...

Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders –– Capital raising was strongly supported by domestic and ...

Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the ...

Intravenous immunoglobulin (IVIG) has anti-inflammatory properties with multiple mechanisms of action. IVIG inhibits autoreactive T cells, suppresses autoantibodies through anti-idiotypic ...

As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase ...